Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?
https://www.zacks.com/stock/news/2227400/henry-schein-hsic-set-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227400
Feb 16, 2024 - Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.
0
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
https://www.zacks.com/stock/news/2227548/corcept-cort-q4-earnings-beat-estimates-korlym-sales-grow?cid=CS-ZC-FT-analyst_blog|earnings_article-2227548
Feb 16, 2024 - Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
0
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
https://www.zacks.com/stock/news/2229472/sarepta-srpt-to-report-q4-earnings-will-it-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2229472
Feb 21, 2024 - Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
0
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
https://www.zacks.com/stock/news/2236810/regenxbio-rgnx-soars-15-on-interim-data-from-dmd-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236810
Mar 06, 2024 - Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
0
GSK Gears Up for Q1 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2260559
Apr 23, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
0
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
https://www.zacks.com/stock/news/2264268/what-s-in-store-for-adma-biologics-adma-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2264268
Apr 29, 2024 - On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
0
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
https://www.zacks.com/stock/news/2266374/sarepta-therapeutics-srpt-q1-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2266374
May 01, 2024 - Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
0
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
https://www.zacks.com/stock/news/2267221/sarepta-srpt-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267221
May 02, 2024 - Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
0